PURPOSE: Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP-hydrolysing enzyme with a central role in striatal signalling and implicated in neuropsychiatric disorders such as Huntington's disease, Parkinson's disease, schizophrenia and addiction. We have developed a novel PDE10A PET ligand, (18)F-JNJ42259152, and describe here its human dynamic biodistribution, safety and dosimetry. METHODS: Six male subjects (age range 23-67 years) underwent ten dynamic whole-body PET/CT scans over 6 h after bolus injection of 175.5 ± 9.4 MBq (18)F-JNJ42259152. Source organs were delineated on PET/CT and individual organ doses and effective dose were determined using the OLINDA software. RESULTS: F-JNJ42259152 was readily taken up by the brain and showed exclusive retention in the brain, especially in the striatum with good washout starting after 20 min. The tracer was cleared through both the hepatobiliary and the urinary routes. No defluorination was observed. Organ absorbed doses were largest for the gallbladder (239 μSv/MBq) and upper large intestine (138 μSv/MBq). The mean effective dose was 24.9 ± 4.1 μSv/MBq. No adverse events were encountered. CONCLUSION: In humans, (18)F-JNJ42259152 has an appropriate distribution, brain kinetics and safety. The estimated effective dose was within WHO class IIb with low interindividual variability. Therefore, the tracer is suitable for further kinetic evaluation in humans.
PURPOSE:Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP-hydrolysing enzyme with a central role in striatal signalling and implicated in neuropsychiatric disorders such as Huntington's disease, Parkinson's disease, schizophrenia and addiction. We have developed a novel PDE10A PET ligand, (18)F-JNJ42259152, and describe here its human dynamic biodistribution, safety and dosimetry. METHODS: Six male subjects (age range 23-67 years) underwent ten dynamic whole-body PET/CT scans over 6 h after bolus injection of 175.5 ± 9.4 MBq (18)F-JNJ42259152. Source organs were delineated on PET/CT and individual organ doses and effective dose were determined using the OLINDA software. RESULTS: F-JNJ42259152 was readily taken up by the brain and showed exclusive retention in the brain, especially in the striatum with good washout starting after 20 min. The tracer was cleared through both the hepatobiliary and the urinary routes. No defluorination was observed. Organ absorbed doses were largest for the gallbladder (239 μSv/MBq) and upper large intestine (138 μSv/MBq). The mean effective dose was 24.9 ± 4.1 μSv/MBq. No adverse events were encountered. CONCLUSION: In humans, (18)F-JNJ42259152 has an appropriate distribution, brain kinetics and safety. The estimated effective dose was within WHO class IIb with low interindividual variability. Therefore, the tracer is suitable for further kinetic evaluation in humans.
Authors: M Giorgi; G Melchiorri; V Nuccetelli; V D'Angelo; A Martorana; R Sorge; V Castelli; G Bernardi; G Sancesario Journal: Neurobiol Dis Date: 2011-04-16 Impact factor: 5.996
Authors: Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Nicholas Seneca; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Victor W Pike; Christer Halldin; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-24 Impact factor: 9.236
Authors: C J Schmidt; D S Chapin; J Cianfrogna; M L Corman; M Hajos; J F Harms; W E Hoffman; L A Lebel; S A McCarthy; F R Nelson; C Proulx-LaFrance; M J Majchrzak; A D Ramirez; K Schmidt; P A Seymour; J A Siuciak; F D Tingley; R D Williams; P R Verhoest; F S Menniti Journal: J Pharmacol Exp Ther Date: 2008-02-20 Impact factor: 4.030
Authors: Zhude Tu; Jinda Fan; Shihong Li; Lynne A Jones; Jinquan Cui; Prashanth K Padakanti; Jinbin Xu; Dexing Zeng; Kooresh I Shoghi; Joel S Perlmutter; Robert H Mach Journal: Bioorg Med Chem Date: 2011-01-22 Impact factor: 3.641
Authors: Judith A Siuciak; Douglas S Chapin; John F Harms; Lorraine A Lebel; Sheryl A McCarthy; Leslie Chambers; Alka Shrikhande; Stephen Wong; Frank S Menniti; Christopher J Schmidt Journal: Neuropharmacology Date: 2006-06-15 Impact factor: 5.250
Authors: Sofie Celen; Michel Koole; Meri De Angelis; Ivan Sannen; Satish K Chitneni; Jesus Alcazar; Stefanie Dedeurwaerdere; Dieder Moechars; Mark Schmidt; Alfons Verbruggen; Xavier Langlois; Koen Van Laere; José Ignacio Andrés; Guy Bormans Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Hao Yang; Francis N Murigi; Zhijian Wang; Junfeng Li; Hongjun Jin; Zhude Tu Journal: Bioorg Med Chem Lett Date: 2014-12-22 Impact factor: 2.823
Authors: Stuart P McCluskey; Christophe Plisson; Eugenii A Rabiner; Oliver Howes Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-21 Impact factor: 9.236